Driehaus Capital Management’s Avidity Biosciences RNAM Stock Holding History

Driehaus Capital Management’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-45,408	Closed	-$3.28M	–	424
2025 Q4	$3.28M	Sell	45,408 -15,169	-25%	-$980K	0.02%	321
2025 Q3	$2.64M	Buy	+60,577	New	+$2.45M	0.02%	340
2025 Q2	–	Sell	-1,270,931	Closed	-$37.5M	–	487
2025 Q1	$37.5M	Buy	1,270,931 +42,873	+3%	+$1.34M	0.36%	87
2024 Q4	$35.7M	Buy	1,228,058 +356,114	+41%	+$14.9M	0.29%	112
2024 Q3	$40M	Buy	+871,944	New	+$37.8M	0.34%	98
2023 Q2	–	Sell	-313,542	Closed	-$4.81M	–	459
2023 Q1	$4.81M	Sell	313,542 -37,703	-11%	-$830K	0.07%	294
2022 Q4	$7.79M	Buy	+351,245	New	+$5.24M	0.12%	237

Other funds holding RNAM

Corsicana & Co Corsicana, Texas $158M AUM

Driehaus Capital Management's RNAM Position: Q1 2026 in Review

Driehaus Capital Management sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 45,408 shares — an estimated $3.28M sold.

Driehaus Capital Management first reported a position in RNAM in Q4 2022 and held it in 7 quarters. The position peaked at $40M in Q3 2024. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

Driehaus Capital Management reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
Driehaus Capital Management sold 45,408 Avidity Biosciences shares in Q1 2026, an estimated $3.28M.
Driehaus Capital Management first reported a position in Avidity Biosciences in Q4 2022 and held it in 7 quarters.
Driehaus Capital Management's Avidity Biosciences position peaked at $40M in Q3 2024.
1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Driehaus Capital Management's 13F filing for Q1 2026, filed 15 May 2026.